BerGenBio
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Manufacturing
Description
BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-06-06 14:47 |
BerGenBio - Disclosure of large shareholding
|
English | 837 bytes | ||
| 2023-06-05 20:11 |
BerGenBio Announces Data from Bemcentinib Trial in Mesothelioma Presented at AS…
|
English | 6.3 KB | ||
| 2023-05-30 16:19 |
BerGenBio to Participate in Investor Webcast and Q&A
|
English | 2.7 KB | ||
| 2023-05-30 11:28 |
BerGenBio ASA: Receipt of subscription rights in the rights issue by primary in…
|
English | 125.5 KB | ||
| 2023-05-30 11:28 |
BerGenBio ASA: Receipt of subscription rights in the rights issue by primary in…
|
English | 2.2 KB | ||
| 2023-05-30 05:00 |
BerGenBio ASA - Commencement of the subscription period for the rights issue
|
English | 113.3 KB | ||
| 2023-05-30 05:00 |
BerGenBio ASA - Commencement of the subscription period for the rights issue
|
English | 20.6 KB | ||
| 2023-05-26 12:41 |
BerGenBio ASA: Approval and publication of prospectus for the preferential Righ…
|
English | 105.1 KB | ||
| 2023-05-26 12:41 |
BerGenBio ASA: Approval and publication of prospectus for the preferential Righ…
|
English | 9.9 KB | ||
| 2023-05-25 06:04 |
Shareholder disclosure
|
English | 93.6 KB | ||
| 2023-05-25 06:04 |
Shareholder disclosure
|
English | 243 bytes | ||
| 2023-05-25 05:00 |
BerGenBio Announces Abstracts Accepted for Presentation at 2023 ASCO
|
English | 4.3 KB | ||
| 2023-05-24 18:12 |
Mandatory notification of trade by related party to Primary Insiders
|
English | 127.1 KB | ||
| 2023-05-24 18:12 |
Mandatory notification of trade by related party to Primary Insiders
|
English | 127.2 KB | ||
| 2023-05-24 18:12 |
Mandatory notification of trade by related party to Primary Insiders
|
English | 1.2 KB |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BerGenBio
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
